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ABSTRACT
Historically, vitamin K antagonists have been
the only class of oral anticoagulants available.
Despite our experience with warfarin over the
past 60 years, its use is associated with several
pharmacokinetic and clinical disadvantages
including unpredictable dosing, frequent
monitoring, and delayed onset and offset.
Edoxaban, an oral direct Xa inhibitor, may
provide clinicians with an additional option in
patients requiring chronic anticoagulation. This
review examines the pharmacology and clinical
data of edoxaban as a therapeutic alternative.
Keywords: Atrial fibrillation; Direct oral
anticoagulant (DOAC); Edoxaban; Factor Xa;
Factor Xa inhibitor; Non-vitamin K




Anticoagulation is a critical component in the
management of venous thromboembolism
(VTE) and atrial fibrillation. Venous
thromboembolism, including deep vein
thrombosis (DVT) and pulmonary embolism
(PE), has an annual incidence rate of
approximately 1 per 1000 people in the
general population. Furthermore, VTE is the
third most common acute cardiovascular
disorder after myocardial infarction and
stroke, affecting approximately 900,000
persons in the United States annually [1, 2].
Atrial fibrillation is the most prevalent cardiac
arrhythmia, affecting over 2.2 million people in
the United States and 4.5 million people in the
European Union [3].
Vitamin K antagonists (VKAs) have been the
standard of care for the prevention and
treatment of VTE, and stroke prevention in
atrial fibrillation patients. Prior to 2009, the
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only oral anticoagulant available in the United
States was warfarin. Three months of warfarin
for idiopathic VTE resulted in a 95% reduction
in recurrent thromboembolism [4]. Warfarin
has been found to reduce the risk of stroke by
64% compared to placebo in patients with atrial
fibrillation [5]. The rate of major bleeding with
warfarin in the setting of venous
thromboembolism has been estimated to be
approximately 6.5% per year, with a range of
3% in low-risk patients to 30% in high-risk
patients [6]. In the setting of atrial fibrillation,
the rate of major bleeding has been estimated to
be approximately 2.3% per year [7]. The
limitations of VKAs are well documented,
including a narrow therapeutic window that
requires monitoring, variable therapeutic
response, delayed onset and offset of action,
dose adjustments, food and drug interactions,
and risk for bleeding.
In 2009, the first oral factor IIa (thrombin)
inhibitor, dabigatran, was approved by the
United States Food and Drug Administration
(FDA) for the prevention of stroke in the setting
of non-valvular atrial fibrillation (NVAF). Two
oral factor Xa (fXa) inhibitors, rivaroxaban and
apixaban, were subsequently FDA-approved for
the same indication (Table 1) [8–11].
Eventually, these agents were all approved for
the prevention and treatment of VTE as well.
These non-vitamin K oral anticoagulants
(NOACs) have challenged the previously
accepted realities of therapeutic monitoring,
bridging regimens, and dietary modifications.
However, these agents are not without their
clinical limitations. A number of
pharmacokinetic drug interactions still must
be considered for appropriate use and dosing.
Additionally, apixaban and dabigatran require
twice-daily dosing, which may negatively
impact patient adherence. These NOACs have
been found to be at least as safe as warfarin.
While approved doses of rivaroxaban and
dabigatran have resulted in similar rates of
major bleeds compared to VKAs, apixaban is
associated with a reduced risk [12]. The NOACs
have resulted in a significant reduction in
intracranial hemorrhage compared to VKAs,
however several of these agents have been
associated with an increase in gastrointestinal
bleeding [13]. With these limitations in mind,
the search for an optimal oral anticoagulant
continues. Edoxaban (Savaysa), a new fXa
inhibitor, was FDA-approved in 2015 and
appears poised to address some of these
practical concerns.
Compliance with Ethics Guidelines
This article is based on previously conducted
studies and does not involve any new studies of




Edoxaban, like rivaroxaban and apixaban, is a
selective fXa inhibitor. Edoxaban inhibits free
fXa without the need of antithrombin (Fig. 1).
This inhibition of fXa in the coagulation
cascade leads to decreased thrombin
generation, and therefore, a reduction in
thrombus formation and progression. The
reduction in thrombin also results in an
indirect inhibition of platelet aggregation.
Changes in the prothrombin time (PT),
international normalized ratio (INR), and
activated partial thromboplastin time (aPTT)
may be observed in patients on therapeutic
edoxaban doses. However, these changes tend
to be small, unpredictable, and highly variable,
so clinicians should not use these markers to
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monitor the anticoagulant effects or titrate the
dose of edoxaban [14].
Pharmacokinetics
The pharmacokinetics of edoxaban have been
shown to be dose dependent following single
doses up to 150 mg and repeated doses up to
120 mg in healthy subjects [15, 16]. Peak plasma
concentrations of the drug occur 1–2 h
following oral administration. The oral
bioavailability is approximately 62%, and
unlike rivaroxaban, the systemic exposure of
edoxaban does not seem to be affected by food.
In vitro, edoxaban is approximately 55%
protein bound. Unchanged edoxaban is the
primary form in plasma. However, minimal
metabolism via hydrolysis, conjugation, and
oxidation by CYP3A4 is present [11]. In a study
examining the elimination of radiolabeled
edoxaban in healthy subjects, approximately
60% of the drug was eliminated in the feces,
with approximately 35% eliminated in the
urine. Over 70% of the drug was eliminated
Table 1 FDA approved dosing regimens for NOACs based on indication [8–11]
Medication Indication Dosea
Dabigatran Stroke and systemic embolism prophylaxis in
NVAF
150 mg PO BID
VTE prophylaxis for recurrent VTE 150 mg PO BID
VTE treatment 150 mg PO BID (5–10 days after parenteral anticoagulants)
Rivaroxaban Stroke and systemic embolism prophylaxis in
NVAF
20 mg PO with evening meal
VTE prophylaxis for recurrent VTE 20 mg PO daily with evening meal
VTE treatment 15 mg PO BID 9 21 days, then 20 mg PO daily with food
VTE prophylaxis for THA or TKA surgery 10 mg PO daily 9 35 days (THA) 10 mg PO
daily 9 12 days (TKA)
Apixaban Stroke and systemic embolism prophylaxis in
NVAF
5 mg PO BID
VTE prophylaxis for recurrent VTE 2.5 mg PO BID
VTE treatment 10 mg PO BID 9 7 days, then 5 mg PO BID
VTE prophylaxis for THA or TKA surgery 2.5 mg PO BID 9 35 days (THA)
2.5 mg PO BID 9 12 days (TKA)
Edoxaban Stroke and systemic embolism prophylaxis in
NVAF
60 mg PO daily
VTE treatment 60 mg PO daily (5–10 days after parenteral anticoagulants)
BID twice daily, FDA Food and Drug Administration, NOAC non-vitamin K oral anticoagulants, NVAF non-valvular atrial
ﬁbrillation, THA total-hip arthroplasty, TKA total-knee arthroplasty, PO by mouth, VTE venous thromboembolism
a Refer to package inserts for dose adjustments based on patient age, weight, and renal function
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unchanged with an elimination half-life of
10–14 h [15, 16]. Patients with mild to
moderate hepatic impairment do not appear
to have any major changes in pharmacokinetic
profiles. However, the pharmacokinetic profile
is affected by renal impairment. Total systemic
exposure increased 32% in patients with
creatinine clearance (CrCl) 51–80 ml/min and
72% in patients with CrCl less than 30 ml/min,
compared to patients with CrCl greater than
80 ml/min [11]. The clinical implications of
these differences in pharmacokinetics will be
discussed later.
Reversal
Similar to other NOACs, the need exists for a
rapid reversal agent. Unlike the anticoagulant
effects of warfarin, which can be reversed
directly with the use of vitamin K, there is no
approved reversal agent specific for the
anticoagulant effects of edoxaban.
Non-specific agents for reversal include
prothrombin complex concentrate (PCC) and
recombinant FVIIa. In a phase I trial evaluating
PCC for the reversal of edoxaban in 110
subjects, PCC was found to reverse the
anticoagulant effects of edoxaban 60 mg in a
dose-dependent fashion. Complete reversal of
bleeding duration and endogenous thrombin
potential and partial reversal of PT was observed
following a dose of 50 IU/kg [17]. While dialysis
is an option for removal of dabigatran in the
setting of acute bleeding due to its low
percentage of protein binding and high renal
clearance, it is not an effective option for
reversal of fXa inhibitors. Edoxaban has a
lower percentage of protein binding than the
other fXa inhibitors, but its degree of renal
clearance is much lower than that of dabigatran
(Table 2) [8–11, 18]. In a study evaluating the
pharmacokinetics and safety of edoxaban in
patients undergoing hemodialysis, patients
receiving hemodialysis (AUC0?? 676.2 ng h/
ml) had only a minor decrease in mean total
exposure compared to those patients off-dialysis
(AUC0?? 691.7 ng h/ml), suggesting that
hemodialysis would not be an efficient means
of drug removal [19].
Several promising antidotes are currently in
development for reversal of edoxaban and other
NOACs. Andexanet alfa (PRT064445) is a
modified, recombinant activated Factor X
(rFXa) produced in Chinese hamster ovary
cells. This modified rFXa lacks intrinsic
procoagulant properties due to a mutation in
Fig. 1 In a, FXa forms a complex with FVa to allow for
conversion of prothrombin to thrombin. In b, FXa
inhibitor binds to FXa, preventing the conversion of
prothrombin to thrombin. In c, FXa inhibitor binds to
andexanet alfa rather than FXa, allowing for formation of
thrombin. Gla Gamma-carboxyglutamic acid
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the serine residue of the amino acid structure.
To prevent competition between this inactive
rFXa and active fXa molecules in the
coagulation cascade, andexanet alfa lacks a
membrane-binding c-carboxyglutamic acid
domain (Fig. 1). Therefore, andexanet alfa has
the capacity to bind direct fXa inhibitors
without interfering with the coagulation
cascade [20, 21]. Several phase 1 and phase 2
trials have shown promise for andexanet alfa’s
ability to reverse the effects of various fXa
inhibitors [20]. One study specific to edoxaban
showed that a single 60-mg dose of edoxaban
was reversed 52% following a 600 mg bolus of
andexanet and by 73% following an 800-mg
bolus. Both bolus doses were followed by a
continuous andexanet infusion of 8 mg/min for
1 h. Within 2 h of stopping the andexanet
infusion, anti-fXa levels returned to those
measured in the group receiving placebo
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infusions [22]. Phase 3 trials investigating this
agent for reversal of NOACs are currently
underway [23, 24].
Another promising antidote under
development is aripazine (PER977). This small
molecule binds non-covalently to and inhibits
the activity of both direct and indirect
anticoagulants, including both oral and
parenteral agents. Unlike andexanet, which is
specific to fXa inhibitors, aripazine has been
shown to have effects on dabigatran as well [20].
Specific to edoxaban, a phase 1 trial was
conducted in which 80 healthy volunteers
received an intravenous bolus dose of
5–300 mg aripazine. In the patients who were
also pretreated with 60 mg edoxaban, the whole
blood clotting time was normalized following a
single 300-mg bolus dose of aripazine. The
anticoagulant effects of aripazine remained
stable over a 24-h period [25]. An additional
phase 2 trial investigating this agent for reversal
of edoxaban is currently underway [26].
Drug Interactions
One benefit of the NOACs is the potential for
fewer drug–drug interactions. However, several
clinically significant drug interactions are worth
noting with edoxaban. The majority of
pharmacokinetic drug interactions result from
inhibition or induction of the P-glycoprotein
(P-gp) efflux transporter which is responsible for
intestinal transport of edoxaban [27–30]. One
study evaluated the effects of various
cardiovascular agents on the pharmacokinetics
of edoxaban (Table 3) [27–29]. Other drugs with
pharmacokinetic interactions with edoxaban
are worth noting. Ketoconazole, erythromycin,
and cyclosporine also inhibit P-gp and
concomitant use with edoxaban resulted in
significant increases in Cmax and AUC.
Rifampin, a P-gp inducer, when administered
along with edoxaban resulted in significantly
lower AUC [14]. Based on these interactions,
patients taking protease inhibitors or
cyclosporine were excluded from phase III
clinical trials evaluating edoxaban [28, 29].
The Hokusai-VTE trial also required a dose
reduction of edoxaban during any acute use of
macrolide antibiotics, ketoconazole, or
itraconazole. Chronic use of these antibiotics
was not allowed [29]. The use of anticoagulants,
antiplatelet drugs, and/or thrombolytics with
edoxaban should be avoided due to the
potential for increased risk of bleeding [11].
Patients receiving dual antiplatelet therapy were
not enrolled in phase III clinical trials
evaluating edoxaban [28, 29]. Low-dose
aspirin, thienopyridines, and non-steroidal
anti-inflammatory drugs were allowed in
clinical trials evaluating edoxaban, and
concomitant use of these medications resulted
in increased rates of clinically relevant bleeding
[11].
Atrial Fibrillation
Edoxaban was studied in a phase II trial for the
prevention of stroke and systemic embolism in
patients with NVAF [31]. This multicenter trial
randomized 1146 patients to one of five
treatment groups including edoxaban 30 mg
PO daily (n = 235), 30 mg PO twice daily
(n = 244), 60 mg PO daily (n = 234), 60 mg PO
twice daily (n = 180), or warfarin titrated to a
goal INR 2–3 (n = 250). While the primary
outcome was the occurrence of major and/or
clinically relevant non-major bleeding, the rate
of stroke and systemic embolism was collected.
Approximately 63% of patients had a CHADS2
score of 2 in each arm. The presence of stroke,
TIA, or systemic embolism was low and no
statistical differences were observed (0.4%
edoxaban 30 mg daily; 1.3% edoxaban 30 mg
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twice daily; 0.4% edoxaban 60 mg daily; 1.1%
edoxaban 60 mg twice daily; 1.6% warfarin).
These data helped investigators chose the
edoxaban 30- and 60-mg doses for the phase
III investigation.
The ENGAGE AF-TIMI 48 trial was a
double-blind, double-dummy, non-inferiority
trial that randomized 21,105 patients to
receive high-dose edoxaban (60 mg daily),
low-dose edoxaban (30 mg daily), or warfarin
titrated to a goal INR 2-3 [28]. Subjects were
enrolled with documented NVAF with a CrCl
greater than 30 ml/min. The mean CHADS2
score was 2.8 in each arm representing a
moderate-to-severe risk population for the
occurrence of the composite primary outcome,
Table 3 Pharmacokinetic drug interactions with edoxaban [27–29]
Concomitant drug Effects on pharmacokinetics Dose considerations
Verapamil Increase in AUC0–24: 52.7%
Increase in Cmax: 53.3%
Increase in 24-h concentration: 29.1%
VTE: dose should be halved
NVAF: dose should be halved
Quinidine Increase in AUC0–24: 76.7%
Increase in Cmax: 85.4%
Increase in 24-h concentration: 11.8%
VTE: dose should be halved
NVAF: dose should be halved
Dronedarone Increase in AUC0–inf: 84.5%
Increase in Cmax: 45.8%
Increase in 24-h concentration: 157.6%
VTE: use is not recommended
NVAF: dose should be halved
Amiodarone Increase in AUC0–inf: 39.8%
Increase in Cmax: 66.0%
Decrease in 24-h concentration: 25.7%
No dose adjustment
Digoxin Increase in AUC0–s: 9.5%
Increase in Cmax: 15.6%
Decrease in 24-h concentration: 9.4%
No dose adjustment
Atorvastatin Increase in AUC0–inf: 1.7%
Decrease in Cmax: 14.2%
Increase in 24-h concentration: 7.9%
No dose adjustment
Ketoconazole Increase in AUC0-inf: 86.7%
Increase in Cmax: 66.9%
Increase in 24-h concentration: 26.8%
VTE: dose should be halved
NVAF: concomitant use should be avoided
Erythromycin Increase in AUC0–inf: 87.0%
Increase in Cmax: 63.1%
Increase in 24-h concentration: 27.8%
VTE: dose should be halved
NVAF: concomitant use should be avoided
AUC area under the curve, Cmax maximum concentration, NVAF non-valvular atrial ﬁbrillation, h hour
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including stroke and non-CNS systemic
embolism. The primary outcome occurred in
1.5% of patients receiving warfarin (1.18%
high-dose edoxaban [Hazard Ratio (HR) 0.79;
97.5% confidence interval (CI) 0.63–0.99;
p\0.001] and 1.61% low-dose edoxaban [HR
1.07; 97.5% CI 0.87–1.31; p = 0.005]). The
intention-to-treat analysis demonstrated a
favorable trend with high-dose edoxaban
(1.57% high-dose edoxaban versus 1.8%
warfarin; p = 0.08) and an unfavorable trend
with low-dose edoxaban (2.04% low-dose
edoxaban; p = 0.10). In a pre-specified analysis,
high-dose edoxaban significantly reduced the
risk of the primary endpoint in patients who
were warfarin-naive patients (HR 0.71; 95% CI
0.56–0.91] [32]. At the end of the study period,
patients in each edoxaban arm were given half
of the treatment dose until they achieved a
therapeutic INR on warfarin. The purpose of
this bridging approach was to reduce the risk of
thrombotic complications during anticoagulant
transition, as observed with rivaroxaban in the
ROCKET-AF trial [33]. Patients randomized to
the high-dose edoxaban were given edoxaban
30 mg daily and the low-dose edoxaban patients
were given edoxaban 15 mg daily. Stroke and
systemic embolism were evenly distributed
across the three treatment groups (seven in
each group). The impact of CrCl on the
occurrence of stroke and systemic embolism
was also closely monitored. The prevention of
thrombosis appeared to diminish in patients
with a higher CrCl. The potential benefits of
edoxaban 60 mg compared to warfarin were
absent with a CrCl of 95 ml/min or greater (HR
1.02 95% CI 0.76–1.38). This directly led to the
FDA approved recommendations to avoid
edoxaban in NVAF with a CrCl greater than
95 ml/min [34].
The safety of antithrombotic therapy with
edoxaban in NVAF has been evaluated in
multiple phase II clinical trials. The major
phase II study conducted by Weitz et al.
described the two once-daily edoxaban
regimens (30 mg once daily and 60 mg once
daily) to have similar safety profiles to warfarin,
with less bleeding than the twice-daily regimens
[31]. Pharmacokinetic analysis demonstrated
that the risk of bleeding correlated best with
trough levels, which were lower with the
once-daily regimens, thus yielding a lower
bleeding rate. Additional phase II trials added
to the data reported by Weitz et al. by
determining that dose adjustment of edoxaban
may be required in patients with low body
weight (B60 kg) due to a higher incidence of all
bleeding [35]. Pooled analysis of phase I and II
trials also suggested that renal insufficiency
(defined as CrCl 30–50 ml/min) and
concomitant P-gp inhibitor treatment may
also influence bleeding risk [36]. Concomitant
aspirin administration may also be an
important covariate for bleeding events, but
this finding has not been shown to be
statistically significant [35]. Overall, in phase II
trials, edoxaban 30 and 60 mg once daily had
rates of bleeding similar to or less than warfarin,
produced treatment emergent adverse events
similar to warfarin, and produced no significant
difference in the incidence of hepatic enzyme
elevations [31, 37]. From these trials, and results
from pooled analyses, the once-daily edoxaban
doses (30 and 60 mg) were selected for further
investigation and comparison with warfarin for
stroke prevention in patients with NVAF in the
phase III ENGAGE AF-TIMI 48 trial [38].
Additionally, an edoxaban dose reduction
(half dose) was recommended in patients with
moderate renal impairment (CrCl 30–50 ml/
min), body weight B60 kg, and in patients
taking strong P-gp inhibitors [36].
In the ENGAGE AF-TIMI 48 trial, the
principal safety endpoint was adjudicated
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major bleeding (defined by the International
Society on Thrombosis and Haemostasis) [28].
Other pertinent safety endpoints included any
bleeding that was fatal, life-threatening,
intracranial, or gastrointestinal, as well as any
clinically relevant non-major bleeding
(CRNMB), or the combination of any major or
CRNMB. Both doses of edoxaban were superior
to warfarin with respect to all significant
bleeding outcomes including major,
life-threatening, CRNMB, minor, and the
combination of major or CRNMB. The
annualized rates of major bleeding were 3.43%
with warfarin, 2.75% with high-dose edoxaban
(HR 0.80; 95% CI 0.71–0.91; p\0.001), and
1.61% (HR 0.47; 95% CI 0.41–0.55; p\0.001)
with low-dose edoxaban (Table 4) [28]. With
regards to the rate of gastrointestinal bleeding,
low-dose edoxaban maintained superiority over
warfarin (HR 0.67; 95% CI 0.53–0.83; p\0.001),
however high-dose edoxaban was associated
with higher rates of gastrointestinal bleeding
compared to warfarin (HR 1.23; 95% CI
1.02–1.50; p = 0.03). The rates of non-bleeding
adverse events were similar in the three
treatment groups. Overall, edoxaban (both
high and low-dose) was shown to be superior
to dose-adjusted warfarin in almost all major
bleeding outcomes, and this superiority was
maintained in the subgroup of patients with a
CrCl\95 ml/min, as well as those who received
a dosage reduction at randomization.
In an indirect treatment comparison analysis
of the NOACs for stroke prevention in NVAF,
some differential safety effects were discovered
with edoxaban (both high- and low-dose) and
the other agents [39]. Overall, high-dose
edoxaban appears to have similar safety to
other newer options but may be associated
with lower risk of major (HR 1.30; 95% CI
1.08–1.57 with rivaroxaban) and major or
CRNMB (HR 1.20; 95% CI 1.08–1.32 with
rivaroxaban) compared to rivaroxaban and
possibly increased risk of major or CRNMB
compared with apixaban (HR 0.79; 95% CI
0.70–0.90 with apixaban). Low-dose edoxaban
appears safer than all other oral agents in terms
of bleeding events. These finding should be
interpreted cautiously as there were important
differences between the trials of these agents
that could have led to the observations. Patient
selection, quality of anticoagulation control
with warfarin (reflected by average time in
therapeutic range), and the presence of dosage
reductions for particular patient characteristics
were not consistent between trials.
Additionally, although adjusted indirect
treatment comparison meta-analysis is an
established statistical technique, the data are
generated using indirect evidence and therefore
are not as precise as what would be possible
with direct comparative data.
Venous Thromboembolism Prophylaxis
Edoxaban has not been FDA-approved for
prophylaxis following orthopedic surgery.
Most clinical studies have used comparators
that are known to be inferior, unavailable in the
United States, or never studied in phase III
trials. The dose finding study for orthopedic
surgery evaluated edoxaban 5 mg (n = 88),
15 mg (n = 92), 30 mg (n = 88), and 60 mg
(n = 88) [40]. This multicenter,
placebo-controlled trial randomized 523
patients following total knee arthroplasty. The
occurrence of any thrombotic event (PE and
DVT) was reduced with higher doses (29.5, 26.1,
12.5, 9.1%) versus placebo arm (48.3%). This
dose-ranging trial helped establish the
edoxaban doses to pursue in future phase III
orthopedic prophylaxis trials. Three Japanese
phase III trials were conducted with edoxaban
for the prevention of VTE in the STARS
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(Studying Thrombosis After Replacement)
program including the STARS E-3 trial
(n = 716) following total knee arthroplasty, the
STARS J-4 (n = 92) following hip fracture
surgery, and the STARS J-V (n = 610) following
hip arthroplasty [41–43]. The STARS E-3 trial
was a double-blind, double-dummy trial that
compared edoxaban 30 mg PO daily to
enoxaparin 20 mg twice daily in patients
following orthopedic surgery [41]. Patients
undergoing total knee arthroplasty were
randomized to receive edoxaban 30 mg daily
(n = 360) 6–24 h post-surgery or enoxaparin
20 mg (n = 356) 24–36 h post-surgery. The
primary outcome of this trial included
symptomatic PE, and symptomatic or
asymptomatic DVT. Edoxaban provided a
statistically significant benefit compared to
low-dose enoxaparin (7.9 vs. 13.9%;
p = 0.010). No statistical differences in the
individual outcomes of PE, symptomatic DVT,
or asymptomatic DVT were observed. The
STARS J-4 trial was a randomized, open-label
trial that compared edoxaban 30 mg PO daily to
enoxaparin 20 mg twice daily in patients
undergoing hip fracture surgery [42]. Patients
were randomized to receive edoxaban (n = 62)
6–24 h post-surgery or enoxaparin (n = 30)
24–36 h post-surgery for 11–14 days following
hip fracture surgery. The secondary outcomes
included efficacy endpoints including the
incidence of thromboembolic events, venous
thromboembolism-related deaths, and all-cause
deaths. The incidence of thromboembolic
events was 6.5% with edoxaban and 3.7% with
enoxaparin, all of which were asymptomatic
DVTs. The STARS J-V trial was a randomized,
double-blind, non-inferiority trial that
compared edoxaban and enoxaparin in
Japanese patients undergoing total hip
arthroplasty [43]. Patients were randomized to
edoxaban 30 mg PO daily 6–24 h post-surgery or
enoxaparin 20 mg twice daily 24–36 h
post-surgery for 11–14 days. The primary
efficacy outcome was defined as a composite
outcome including symptomatic and
asymptomatic DVT, and PE. The composite
outcome occurred in 2.4% of edoxaban
patients and 6.9% of enoxaparin patients
(p\0.001 for non-inferiority, p = 0.0157 for
superiority). The difference in the primary
outcome was largely driven by the incidence
of asymptomatic DVT (2.4% edoxaban versus
6.5% enoxaparin). Fuji and colleagues studied
the impact of renal function in patients treated
with edoxaban following total knee
arthroplasty, total hip arthroplasty, and hip
fracture surgery [44]. Patients with CrCl
50–80 ml/min were given edoxaban 30 mg PO
daily (n = 30), patients with CrCl between 20
and 30 ml/min were given edoxaban 15 mg PO
daily (n = 22) or fondaparinux 1.5 mg SQ daily
(n = 21), and patients with a CrCl between 15
and 20 ml/min were given edoxaban 15 mg PO
daily. No significant reductions in embolism or
death occurred in this population.
The safety of edoxaban for the prevention of
VTE following orthopedic surgery was also
assessed. In a Japanese patient population
following total knee arthroplasty, edoxaban at
doses of 5, 15, 30, and 60 mg once daily for
11–14 days produced no difference in major or
CRNMB versus placebo (1.9–4.7% in edoxaban
groups versus 3.9% in placebo group) [40]. The
incidence of treatment-related all bleeding
events (major, CRNMB, and minor) was
significantly increased in the edoxaban 60 mg
once-daily group compared with placebo (17 vs.
6.9%, respectively; p = 0.025), but was not
increased with the other edoxaban doses (5.8,
10.4, and 10.7% with edoxaban 5, 15, and
30 mg once daily, respectively) [40]. Edoxaban
at doses of 15, 30, 60, or 90 mg once daily for
7–10 days produced no significant difference in
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major and/or CRNMB versus dalteparin sodium
(initially 2500 IU, followed by 5000 IU) once
daily in a Caucasian population following total
hip replacement, and had a comparable
incidence of major and CRNMB versus
subcutaneous enoxaparin sodium 20 mg twice
daily following total hip arthroplasty [45].
Treatment emergent adverse events with
edoxaban were similar to the comparator
groups in all trials and there was no indication
of hepatotoxicity. Overall, in phase II studies,
edoxaban 30 mg once daily appeared to be well
tolerated in both total knee and total hip
arthroplasty and led to that dose being utilized
for phase III testing.
Regarding safety, STARS J-4, J-V, and E-3
compared edoxaban 30 mg once daily to
enoxaparin 20 mg twice daily (standard dosing
in Japan), no significant difference in major and
CRNM bleeding events was seen (major and
CRNMB occurred in 6.2, 3.4, and 2.6% in the
edoxaban groups in the STARS E-3, J-4 and J-V
trials, respectively) [41–43]. However, these
studies were generally underpowered to detect
small differences in bleeding rates and the
dosing of enoxaparin 20 mg twice daily may
not allow extrapolation of these studies to other
regions. Elevations in serum aminotransferase
levels had a low incidence within the edoxaban
groups and occurred less often than within the
enoxaparin groups, a finding consistent with
the results of a retrospective comparison
between edoxaban, fondaparinux, and
enoxaparin [46].
Venous Thromboembolism Treatment
The Hokusai-VTE trial was a double-blind,
non-inferiority trial that compared the safety
and efficacy of edoxaban in the treatment of
VTE [29]. Investigators randomized 8292
patients to receive edoxaban 30 or 60 mg
(n = 4118) or warfarin (n = 4122). All patients
received open-label enoxaparin or
unfractionated heparin for at least 5 days, with
a median duration of 7 days. Edoxaban 60 mg
(n = 3385) was recommended for patients with
a CrCl greater than 50 ml/min, and edoxaban
30 mg (n = 733) was administered to patients
with a CrCl between 30 and 50 ml/min.
Warfarin was monitored and titrated to a goal
INR 2–3 for 3–12 months, with 40% of patients
receiving the full 12 months. Patients were
considered for inclusion who experienced a
DVT (n = 4921) and/or PE (n = 3319). The
severity of the index event was similar in the
two treatment groups. The recurrence of
thromboembolism or VTE-related death
occurred in 3.2% of edoxaban patients and
3.5% of warfarin patients (HR 0.89 95% CI
0.70–1.13; p\0.001 for non-inferiority). No
differences were observed with DVT alone,
non-fatal PE, or fatal PE. Additionally, no
differences in the primary outcome were seen
in patients when the index event was a DVT or
PE. The non-inferiority of edoxaban was
maintained in those patients qualifying for the
low dose compared to warfarin (HR 0.73 95% CI
0.42–1.26). Other trials examining target
specific agents in the treatment of VTE have
had a relatively small subgroup of patients with
cancer at baseline. This trial has one of the
largest cancer subgroups with 378 patients in
the edoxaban arm (9.2%) and 393 patients in
the warfarin arm (9.5%).
The primary safety outcome measured was
the incidence of major or CRNMB [29]. Major
bleeding was defined by the International
Society on Thrombosis and Haemostasis and
CRNMB was defined as any overt bleeding that
did not meet the criteria for major bleeding but
was associated with the need for medical
intervention, contact with a physician, or
interruption of the study drug or with
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discomfort or impairment of activities of daily
life. The primary safety outcome occurred
significantly less in the edoxaban group
compared to warfarin, 8.5 and 10.3%,
respectively (HR 0.81; 95% CI 0.71–0.94;
p = 0.004) (Table 5) [29]. There were
numerically fewer fatal and intracranial
bleeding events with edoxaban; however, this
was not statistically significant. Major bleeding
within this patient group was also numerically
lower with the reduced edoxaban dose (1.5%
with edoxaban compared with 3.1% with
warfarin, HR 0.50; 95% CI 0.24–1.03), but this
was not statistically significant. Overall, the
Hokusai-VTE trial established that in patients
with acute VTE, edoxaban once daily was
superior to warfarin with respect to bleeding,
and in patients at a potential higher risk of
bleeding (due to either renal impairment or low
body weight), halving the dose of edoxaban to
30 mg significantly reduced bleeding while
maintaining efficacy.
In an indirect treatment comparison analysis
of the NOACs for the treatment of acute VTE,
the adjusted risk of major bleeding was not
significantly different between edoxaban and
either rivaroxaban or dabigatran but did appear
to be potentially increased in comparison to
apixaban (Relative Risk 2.74; 1.40–5.39) [47].
The required use of parenteral anticoagulation
treatment in the Hokusai-VTE trial, as well as a
longer overall mean treatment duration
(8.3 months versus 6 months, in Hokusai-VTE
and AMPLIFY, respectively) could have
potentially favored the lower bleeding with
apixaban, so this finding should be interpreted
cautiously. Additionally, though adjusted
indirect treatment comparison meta-analysis is
an established statistical technique, the data are
generated using indirect evidence and therefore
are not as precise as what would be possible
with direct comparative data.
Clinical Considerations
Laboratory Monitoring
One of the biggest advantages of the NOACs is
their predictable pharmacokinetic profile. This
translates to the absence of routine monitoring
in clinical practice. However, some clinical
situations require the need for urgent and
reliable monitoring such as surgery, overdoses,
and bleeding. Edoxaban transiently increases
the PT and aPTT in a concentration dependent
manner; however, clotting times can
significantly vary based on reagents and
instrumentation. Furthermore, these
coagulation assays measure the time to the
initiation of clot formation and are not ideal to
assess the effectiveness of edoxaban. One
comparison measured the effect of edoxaban
on seven PT reagents [48]. While the PT results
linearly correlated to edoxaban plasma
concentrations, the magnitude of the PT
change among the reagents varied
considerably. This variability persisted even
when the PT was converted to an INR. While
aPTT prolongation also increased with
edoxaban in a concentration-dependent
manner, the variability among eight aPTT
reagents was smaller. While these assays might
be helpful in evaluating edoxaban compliance,
they are likely not helpful in evaluating the
degree of anticoagulation or need for titration.
The anticoagulant effect of edoxaban has also
been measured using a thrombin generation
assay in both platelet-poor and platelet-rich
plasma. Edoxaban delayed both the initiation
and propagation phase of thrombin generation.
The thrombin generation assay was three times
more sensitive to edoxaban than the PT and
aPTT suggesting it could be used to measure
edoxaban activity at trough concentrations. The
dilute Russell’s viper venom time (dRVVT) may
be another possible alternative to estimate the
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anticoagulation activity produced by edoxaban
[49]. One study reported the anticoagulation
effects of each NOAC, including edoxaban,
using four dRVVT reagents. Each assay was
highly sensitive and increased in a
concentration-dependent manner with
edoxaban. While this method is commercially
available and easy to perform, it may not be
routinely accessible at hospitals and is an
expensive alternative.
Transition Several clinical scenarios may
occur that require initiation, discontinuation,
or transition between edoxaban and a different
anticoagulant. Bridging therapy is not necessary
when initiating edoxaban due to its rapid onset
of action. Edoxaban should be discontinued
24 h prior to surgical or other invasive
procedures [11]. Transitioning from one
anticoagulant to another should balance the
risk for bleeding and thrombosis. When
switching from warfarin, edoxaban should be
initiated when the INR is\2.5. The conversion
of edoxaban to warfarin can be accomplished
using two different strategies. A parenteral
agent can be initiated when the next
edoxaban dose is scheduled, followed by a
traditional bridging approach to warfarin.
Edoxaban can also be converted to warfarin
using half the edoxaban dose until a
stable INR[2.0 is achieved [33]. An oral
transition from edoxaban to warfarin was
successfully utilized in the ENGAGE AF-TIMI
48 trial to reduce the risk of thrombosis
following edoxaban discontinuation.
Education
Patients should be involved in the decision to
use edoxaban for approved indications
balancing patient-specific factors (e.g., cost,
health literacy, adherence) and medical
factors (e.g., renal function, concomitant
medications). Similar to other anticoagulants,
patients prescribed edoxaban should be advised
on the signs and symptoms of bleeding.
Additionally, the patient should be instructed
to take edoxaban at the same time each day
and the importance of adherence should be
emphasized as the anticoagulant activity
returns to baseline at 24 h. While the need for
routine therapeutic monitoring is not
necessary, patients prescribed edoxaban may
still benefit from frequent follow up to
reinforce adherence and assess patient
satisfaction. Historically, practitioners have
focused on renal impairment when evaluating
anticoagulation dosing. Practitioners should be
reminded that the appropriateness of edoxaban
requires evaluation of both normal and
impaired renal function in the setting of
NVAF. Given the number of indications and
diversity in strategies used for initiation,
transition, and discontinuation of each
NOAC, general practitioners may benefit from
a closed formulary or clinical assistance
protocols.
CONCLUSIONS
Edoxaban has emerged as an alternative to an
ever-growing class of selective oral
anticoagulants. It has been shown to be a safe
and effective option for the prevention of stroke
in the setting of NVAF and the treatment of
VTE. Edoxaban has several clinical advantages
including a once-daily regimen, the lack of need
for bridging or routine therapeutic monitoring,
and absence of food-drug interactions. Renal
function and P-gp drug interactions will
challenge its acceptance as an alternative to
traditional and other novel anticoagulants.
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